Hi Guest Login
Home > Oncotype Dx Dcis Test > Mumbai
MAX@Home offers the Oncotype DX DCIS Test, a specialised genomic test that helps doctors evaluate the risk of recurrence in patients diagnosed with DCIS (Ductal Carcinoma In Situ). This test supports better-informed decisions about the need for radiation therapy after surgery.
The Oncotype Dx DCIS (ductal carcinoma in situ) test is a genomic test for early-stage breast cancer to predict its recurrence risk, helping doctors decide which treatment therapy can be given post-surgery based on individual needs and condition.
Eligibility check: Our healthcare team carefully reviews the patient's medical history and condition before the DCIS test.
Sample Collection: A tumor tissue sample is collected from the respective MAX Labs or hospital, where it is stored.
Genomic Analysis: The sample is analysed at our laboratory using advanced genomic technologies
Test Report Generation: A detailed report with the DCIS score is generated and shared with the treating doctor to guide further treatment decisions.
Doctor Discussion: Based on your DCIS score, your doctor will discuss the most appropriate treatment plan and guide you at every stage of your care.
Comfort: MAX@Home provides tumor sample pickup directly from the hospital or lab, eliminating the need for travel and ensuring a stress-free experience.
Doctor-Guided Care: Our oncologists coordinate throughout the entire treatment process to support accurate, personalized treatment decisions.
Trusted and Clinically Proven Test: The Oncotype DX DCIS Test is globally recognised and trusted by oncologists for accurate breast cancer treatment planning.
Mumbai Coverage: Our Oncotype Dx DCIS test services are available across Mumbai, ensuring timely and reliable support wherever you are.
The DCIS score, which ranges from 0 to 100, predicts a 10-year risk of cancer recurrence (DCIS or invasive cancer) in the same breast following breast-conserving surgery.
DCIS Score Interpretation Table:
|
DCIS Score Range |
Risk Level |
What It Means |
How It Helps in Treatment Decisions |
|
0 – 38 |
Low Risk |
Low chance of cancer returning in the same breast within 10 years after surgery |
Radiation therapy may not be necessary; the doctor may suggest monitoring or hormonal therapy |
|
39–54 |
Intermediate Risk |
Moderate chance of DCIS or invasive cancer recurrence |
The doctor will assess whether radiation therapy may provide benefit based on individual factors |
|
55–100 |
High Risk |
Higher chance of cancer returning in the same breast |
Radiation therapy is more likely to be recommended to reduce the recurrence risk |
Key notes:
NOTE: Your oncologist will interpret the score in conjunction with age, tumor size, and pathology information to determine the best treatment plan.
MAX@Home offers advanced Oncotype DX DCIS testing, including tissue sample collection and expert oncologist support, across Mumbai.
Schedule your Oncotype DX DCIS test today, or call us now to speak with our care team for more details
Read More